



MannKind Triples Production Capacity for Afrezza

07/31/15

VALENCIA, Calif., July 31, 2015 (GLOBE NEWSWIRE) -- **MannKind Corporation** (Nasdaq:MNKD) today announced that it has completed the validation of two additional filling lines for the manufacture of Afrezza® (insulin human) inhalation powder. Material produced during the validation runs, including the recently approved 12 unit cartridges, will be supplied to Sanofi to support the launch of the new dosage strength, which is expected later this quarter.

"With the completion of the validation effort, which began last quarter, we can support a demand of more than 300 million cartridges per year," stated Hakan Edstrom, President and CEO of MannKind Corporation. "The addition of the 12 unit cartridge will provide patients with another option to receive their prescribed dose."

About MannKind Corporation

MannKind Corporation (Nasdaq:MNKD) focuses on the discovery and development of therapeutic products for patients with diseases such as diabetes. MannKind maintains a website at <http://www.mannkindcorp.com> to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.

Forward-Looking Statements

This press release contains forward-looking statements that involve risks and uncertainties. Words such as "believes", "anticipates", "plans", "expects", "intend", "will", "goal", "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon the MannKind's current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, MannKind's dependency on Sanofi for commercialization of Afrezza, Sanofi and MannKind's ability to launch new dosage strengths within expected timelines, MannKind's ability to manufacture Afrezza in sufficient quantities to meet demand and other risks detailed in MannKind's filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the year ended December 31, 2014 and the Quarterly Report on Form 10-Q for the quarter ended March 31, 2015. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.

CONTACT: Company Contact:

Matthew J. Pfeffer

Chief Financial Officer

661-775-5300 ☐

mpfeffer@mannkindcorp.com

[MannKind Corporation Logo](#)

Source: MannKind Corporation

News Provided by Acquire Media